Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:5/1/2008

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in two upcoming conferences in May:

-- The Leerink Swann "Conquering Cancer with Novel Therapeutics"

Roundtable Conference on May 9 at 1:35 p.m. Eastern Time at the Grand

Hyatt New York

-- The CitiGroup Health Care Conference on May 21 at 9:30 a.m. Eastern

Time at the New York Hilton

A live audio webcast of the presentation at CitiGroup will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a Phase 1 clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional inform
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... ... August 25, 2015 , ... A new ... cancerous is described by University of Illinois researchers in the Journal of ... , In “ Breast cancer diagnosis using spatial light interference microscopy ,” published ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... note: Recently the Wisconsin Technology Network sat down ... Technology Council , to discuss the basic tenants and ... Wisconsins technology space grow. This is the first portion ... faces and how the Wisconsin Technology Council is working ...
... Sonic Foundry Inc . has introduced two ... distribute rich media for a variety of uses. ... real-time, rich media technology, are intended to enable ... needed for corporate communications, Web-based education, online training, ...
... Camtronics Medical Systems has announced that its ... with six terabytes of storage for digital cardiovascular images ... about two years worth of study results, which clinicians ... hospital or over the Web from outreach clinics. In ...
Cached Biology Technology:WTN exclusive interview with Tom Still, Wisconsin Technology Council 2WTN exclusive interview with Tom Still, Wisconsin Technology Council 3WTN exclusive interview with Tom Still, Wisconsin Technology Council 4WTN exclusive interview with Tom Still, Wisconsin Technology Council 5Sonic Foundry announces new Mediasite products 2
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... (April 6, 2009) Cell Press, an imprint of Elsevier, ... well as Current Biology and The American ... Library Association,s (SLA) Top 100 Journals in Biology and Medicine ... compiled by the 680-plus members of the SLA,s Biomedical and ...
... experimental vaccine that triggers the patient,s immune system to ... promise for the treatment of early lung cancer. ... the vaccine called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, which is ... Rush is one of only five hospitals in Illinois ...
... systems for splitting water into hydrogen and oxygen, driven ... science today, underpinning the long term potential of hydrogen ... exist today are very inefficient and often require additional ... is important to establish new mechanisms by which water ...
Cached Biology News:3 prominent Cell Press journals named among the 100 most influential journals in past 100 years 2Novel lung cancer vaccine shows promise in fighting early-stage lung cancer 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 3
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: